15380

543904

MANKIND

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

MANKIND PHARMA LIMITED Share Price Today

MANKIND PHARMA LIMITED is currently trading at ₹2381.1, up by ₹8.4 from the previous close. The stock touched an intraday high of ₹2419.00 and a low of ₹2368.10 during the latest trading session. Over the past one year, MANKIND PHARMA LIMITED has delivered a loss of 0.37%, while the stock has gained 0.09% in the last one month.

MANKIND PHARMA LIMITED performance

Today’s low Today’s high
₹ 2368.10 ₹ 2419.00
₹ 2381.10
52 week low 52 week high
₹ 1909.70 ₹ 2716.50
₹ 2381.10
Open Price ₹ 2419.00
Prev. Close ₹ 2372.70
Volume (Shares) 286099.00
Total traded value ₹ 6812.30
Upper Circuit ₹ 2609.90
Lower Circuit ₹ 2135.50
info

Investment Returns

Over 1 Month 0.09% Over 3 Months 7.84% Over 6 Months 9.28% Over 1 Year -0.37%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

MANKIND PHARMA LIMITED fundamentals


  • Market cap (Cr) 98,338.50
  • P/E Ratio (TTM) 48.23
  • Beta 0.72
  • Book Value / share 397.02
  • Return on equity 13.89%
  • EPS (TTM) 51.38
  • Dividend yield 0.04%
  • Net profit/quarter (Cr) 713.61
info icon alternate text
  • Market cap (Cr) 98,270.30
  • P/E Ratio (TTM) 48.23
  • Beta 0.59
  • Book Value / share 397.02
  • Return on equity 13.89%
  • EPS (TTM) 51.38
  • Dividend yield 0.04%
  • Net profit/quarter (Cr) 713.61
info icon alternate text

MANKIND PHARMA LIMITED Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars MAR 2026 (Values in Cr)
Revenue 2581.82
Operating Expense 1897.69
Net Profit 713.61
Net Profit Margin (%) 27.63
Earnings Per Share (EPS) 17.29
EBITDA 1022.72
Effective Tax Rate (%) 9.44
Particulars DEC 2025 (Values in Cr)
Revenue 2632.68
Operating Expense 2100.48
Net Profit 448.88
Net Profit Margin (%) 17.05
Earnings Per Share (EPS) 10.87
EBITDA 751.34
Effective Tax Rate (%) 11.16
Particulars SEP 2025 (Values in Cr)
Revenue 2608.78
Operating Expense 2161.81
Net Profit 458.90
Net Profit Margin (%) 17.59
Earnings Per Share (EPS) 11.12
EBITDA 770.85
Effective Tax Rate (%) 12.52
Particulars JUN 2025 (Values in Cr)
Revenue 2541.36
Operating Expense 2111.92
Net Profit 412.76
Net Profit Margin (%) 16.24
Earnings Per Share (EPS) 10.00
EBITDA 737.29
Effective Tax Rate (%) 16.38
Particulars MAR 2025 (Values in Cr)
Revenue 2119.46
Operating Expense 2054.52
Net Profit 238.16
Net Profit Margin (%) 11.23
Earnings Per Share (EPS) 5.70
EBITDA 561.35
Effective Tax Rate (%) 16.27
Particulars MAR 2026 (Values in Cr)
Revenue 10421.18
Operating Expense 8326.04
Net Profit 2037.56
Net Profit Margin (%) 19.55
Earnings Per Share (EPS) 49.37
EBITDA 3305.78
Effective Tax Rate (%) 11.98
Particulars MAR 2025 (Values in Cr)
Revenue 9507.41
Operating Expense 7854.33
Net Profit 1785.99
Net Profit Margin (%) 18.78
Earnings Per Share (EPS) 44.22
EBITDA 2918.24
Effective Tax Rate (%) 19.64
Particulars MAR 2024 (Values in Cr)
Revenue 8629.25
Operating Expense 6714.55
Net Profit 1876.16
Net Profit Margin (%) 21.74
Earnings Per Share (EPS) 45.52
EBITDA 2536.79
Effective Tax Rate (%) 18.88
Particulars MAR 2023 (Values in Cr)
Revenue 8127.15
Operating Expense 6727.10
Net Profit 1248.26
Net Profit Margin (%) 15.35
Earnings Per Share (EPS) 31.16
EBITDA 1860.16
Effective Tax Rate (%) 20.12
Particulars MAR 2022 (Values in Cr)
Revenue 7486.22
Operating Expense 5818.59
Net Profit 1389.42
Net Profit Margin (%) 18.55
Earnings Per Share (EPS) 34.68
EBITDA 2041.88
Effective Tax Rate (%) 25.75
Particulars MAR 2025 (Values in Cr)
Book Value / Share 347.37
ROE % 14.83
ROCE % 16.04
Total Debt to Total Equity 0.37
EBITDA Margin 26.60
Particulars MAR 2024 (Values in Cr)
Book Value / Share 233.73
ROE % 23.12
ROCE % 27.89
Total Debt to Total Equity 0.02
EBITDA Margin 27.40
Particulars MAR 2023 (Values in Cr)
Book Value / Share 185.61
ROE % 19.27
ROCE % 23.11
Total Debt to Total Equity 0.08
EBITDA Margin 23.35
Particulars MAR 2022 (Values in Cr)
Book Value / Share 153.65
ROE % 26.72
ROCE % 33.43
Total Debt to Total Equity 0.10
EBITDA Margin 28.29
Particulars MAR 2021 (Values in Cr)
Book Value / Share 117.88
ROE % 31.51
ROCE % 39.19
Total Debt to Total Equity 0.05
EBITDA Margin 29.48
Particulars MAR 2025 (Values in Cr)
Book Value / Share 354.83
ROE % 13.89
ROCE % 14.88
Total Debt to Total Equity 0.30
EBITDA Margin 28.95
Particulars MAR 2024 (Values in Cr)
Book Value / Share 242.21
ROE % 20.25
ROCE % 23.35
Total Debt to Total Equity 0.00
EBITDA Margin 27.90
Particulars MAR 2023 (Values in Cr)
Book Value / Share 194.31
ROE % 17.43
ROCE % 20.91
Total Debt to Total Equity 0.05
EBITDA Margin 22.89
Particulars MAR 2022 (Values in Cr)
Book Value / Share 163.27
ROE % 24.65
ROCE % 31.42
Total Debt to Total Equity 0.07
EBITDA Margin 27.28
Particulars MAR 2021 (Values in Cr)
Book Value / Share 118.18
ROE % 25.86
ROCE % 33.63
Total Debt to Total Equity 0.01
EBITDA Margin 27.61
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 554.50
Total Assets 27759.53
Total Liabilities 27759.53
Total Equity 14568.18
Share Outstanding 41
Price to Book Ratio 6.83
Return on Assets (%) 7.17
Return on Capital (%) 8.64
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 708.10
Total Assets 11963.25
Total Liabilities 11963.25
Total Equity 9575.79
Share Outstanding 40
Price to Book Ratio 9.48
Return on Assets (%) 15.98
Return on Capital (%) 19.58
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 453.19
Total Assets 9715.44
Total Liabilities 9715.44
Total Equity 7623.29
Share Outstanding 40
Price to Book Ratio 0.00
Return on Assets (%) 13.19
Return on Capital (%) 16.46
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 405.94
Total Assets 9147.73
Total Liabilities 9147.73
Total Equity 6316.31
Share Outstanding 40
Price to Book Ratio 0.00
Return on Assets (%) 15.67
Return on Capital (%) 19.95
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 700.74
Total Assets 6372.63
Total Liabilities 6372.63
Total Equity 4862.88
Share Outstanding 40
Price to Book Ratio 0.00
Return on Assets (%) 19.85
Return on Capital (%) 24.82
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 305.87
Total Assets 23828.32
Total Liabilities 23828.32
Total Equity 14640.27
Share Outstanding 41
Price to Book Ratio 6.83
Return on Assets (%) 8.16
Return on Capital (%) 8.89
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 483.88
Total Assets 11516.39
Total Liabilities 11516.39
Total Equity 9702.77
Share Outstanding 40
Price to Book Ratio 9.48
Return on Assets (%) 16.29
Return on Capital (%) 19.31
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 155.15
Total Assets 9371.12
Total Liabilities 9371.12
Total Equity 7783.91
Share Outstanding 40
Price to Book Ratio 0.00
Return on Assets (%) 13.32
Return on Capital (%) 16.04
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 138.84
Total Assets 8938.70
Total Liabilities 8938.70
Total Equity 6540.45
Share Outstanding 40
Price to Book Ratio 0.00
Return on Assets (%) 15.54
Return on Capital (%) 19.23
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 476.94
Total Assets 5880.33
Total Liabilities 5880.33
Total Equity 4734.27
Share Outstanding 40
Price to Book Ratio 0.00
Return on Assets (%) 18.44
Return on Capital (%) 22.45
Particulars MAR 2025 (Values in Cr)
Net Income 2524.78
Cash from Operations 2980.13
Cash from Investing -12682.95
Cash from Financing 10232.56
Net change in Cash -37.01
Free Cash Flow 3440.92
Particulars MAR 2024 (Values in Cr)
Net Income 2399.35
Cash from Operations 2593.97
Cash from Investing -2081.69
Cash from Financing 5.27
Net change in Cash 76.02
Free Cash Flow 2909.29
Particulars MAR 2023 (Values in Cr)
Net Income 1671.23
Cash from Operations 2136.39
Cash from Investing -1054.12
Cash from Financing -739.72
Net change in Cash 19.44
Free Cash Flow 2925.41
Particulars MAR 2022 (Values in Cr)
Net Income 1974.60
Cash from Operations 1419.28
Cash from Investing -1369.14
Cash from Financing 604.62
Net change in Cash 155.25
Free Cash Flow 1884.15
Particulars MAR 2021 (Values in Cr)
Net Income 1691.61
Cash from Operations 1591.31
Cash from Investing -1222.21
Cash from Financing -7.81
Net change in Cash -92.77
Free Cash Flow 1896.73
Particulars MAR 2025 (Values in Cr)
Net Income 2390.36
Cash from Operations 2793.64
Cash from Investing -12114.68
Cash from Financing 9845.34
Net change in Cash 52.82
Free Cash Flow 3092.06
Particulars MAR 2024 (Values in Cr)
Net Income 2325.72
Cash from Operations 2157.08
Cash from Investing -1665.19
Cash from Financing -4.73
Net change in Cash 66.16
Free Cash Flow 2374.95
Particulars MAR 2023 (Values in Cr)
Net Income 1562.83
Cash from Operations 2084.05
Cash from Investing -1040.61
Cash from Financing -710.41
Net change in Cash 47.96
Free Cash Flow 2632.41
Particulars MAR 2022 (Values in Cr)
Net Income 1871.43
Cash from Operations 1281.66
Cash from Investing -1360.26
Cash from Financing 578.62
Net change in Cash 39.80
Free Cash Flow 1583.01
Particulars MAR 2021 (Values in Cr)
Net Income 1440.20
Cash from Operations 1419.70
Cash from Investing -1127.15
Cash from Financing 88.86
Net change in Cash -15.96
Free Cash Flow 1614.77
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 32.40 13.39 1.56 248.29 23.12 38.85
BLISS GVS PHARMA LTD 438.10 35.56 3.89 4646.32 118.35 462.70
CIPLA LTD 1388.80 29.47 3.25 112193.56 1165.55 1672.20
FERMENTA BIOTECH LIMITED 338.80 14.94 2.45 997.12 256.40 399.00
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 32.40 22.66 4.17 248.29 23.12 38.85
AMRUTANJAN HEALTH CARE LTD. 557.75 25.00 4.35 1612.49 490.00 789.95
ASTRAZENECA PHARMA INDIA LTD. 8243.90 107.66 23.61 20609.75 7630.00 10653.05
BLISS GVS PHARMA LTD 438.10 47.26 4.02 4646.32 118.35 462.70

MANKIND PHARMA LIMITED shareholding pattern

Holding
2.64%
72.65%
10.24%
14.45%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

News

Left Arrow
Right Arrow

MANKIND PHARMA LIMITED Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
2381.10 0.35 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 2374.00
  • 26 Days 2368.60
  • 10 Days 2376.20
  • 50 Days 2319.60
  • 12 Days 2378.30
  • 100 Days 2273.00
  • 20 Days 2377.50
  • 200 Days 2286.00
2377.40 PIVOT
First Support 2345.80 First Resistance 2404.30 Second Support 2318.90 Second Resistance 2435.90 Third Support 2287.30 Third Resistance 2462.80
RSI 51.93 ADX 25.17 MACD 9.69 Williams % R -54.99 Commodity Channel Index (CCI) -31.85
Date 2026-06-12 Week 136320.00 Same Day 159114.00 Month 377237.00
1 Year 0.72 3 Year 0.52
Over 1 Month
0.09% down
Over 1 Year
-0.37% down
Over 3 Months
7.84% down
Over 3 Years
17.31% down
Over 6 Months
9.28% down
Over 5 Years
0.00% down

MANKIND PHARMA LIMITED Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
08 Aug 2025 1.0 Interim 08 Aug 2025 Equity shares
Dividend date Dividend amount Dividend type Record date Instrument type
08 Aug 2025 1.0 Interim 08 Aug 2025 Equity shares

Top Gainers

Top Losers

stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Mankind Pharma Ltd?

Answer Field

Mankind Pharma Ltd share price is for NSE ₹ 2,381.10 & for BSE ₹ 2,390.40 as on Jun 12 2026 03:30 PM.

What is the Market Cap of Mankind Pharma Ltd Share?

Answer Field

The market cap of Mankind Pharma Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on Jun 12 2026 03:30 PM.

What is the 52 Week High and Low of Mankind Pharma Ltd?

Answer Field

The 52 Week High and Low of Mankind Pharma Ltd for NSE is ₹ 2,716.50 and ₹ 1,909.70 and for BSE is ₹ 2,726.75 and ₹ 1,909.90.

What is 1 year return for Mankind Pharma Ltd?

Answer Field

The 1 year returns on the stock has been -0.37%.

What is the P/E Ratio of Mankind Pharma Ltd Share?

Answer Field

As on Jun 12 2026 03:30 PM the price-to-earnings (PE) ratio for Mankind Pharma Ltd share is 48.23.

What is the PB ratio of Mankind Pharma Ltd Share?

Answer Field

As on Jun 12 2026 03:30 PM, the price-to-book (PB) ratio for Mankind Pharma Ltd share is 397.02.

How to Buy Mankind Pharma Ltd Share?

Answer Field

You can trade in Mankind Pharma Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Mankind Pharma Ltd Share on Bajaj Broking App?

Answer Field

To buy Mankind Pharma Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Mankind Pharma Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|